Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Soft Robotic Medical Device to Benefit Patients with Heart Failure

XTALKS VITALS NEWS

Heart

The blood-free pump uses compressed air to contract along with the heart’s natural rhythm and strengthen the organ’s function.

Share this!

January 23, 2017 | by Sarah Hand, M.Sc.

A soft robotic sleeve which supports contraction of the heart muscle has been developed by researchers at Harvard University and Boston Children’s Hospital. The blood-free pump uses compressed air to contract along with the heart’s natural rhythm and strengthen the organ’s function.

Patients with heart failure are often outfitted with a left ventricular assist device (LVAD), which can prologue life. Unfortunately, these medical devices carry inherent risks, such as stroke, requiring patients to be prescribed anticoagulant drugs.

In comparison, the robotic device does not come in contact with a patient’s blood, eliminating the need for blood thinners and reducing the risk of infection. The soft robotic sleeve also doesn’t produce disruptive changes in blood flow that can lead to some of the negative side effects associated with LVADs.

The medical device is composed of silicone, and the size and fit can be adjusted on an individual basis. According to the researchers – whose article was published in the journal, Science Translational Medicine – the device could benefit patients on the transplant list who are waiting for a new heart.



“The cardiac field had turned away from idea of developing heart compression instead of blood-pumping VADs due to technological limitations, but now with advancements in soft robotics it’s time to turn back,” said Dr. Frank Pigula, a cardiothoracic surgeon, and one of the authors of the study. “Most people with heart failure do still have some function left; one day the robotic sleeve may help their heart work well enough that their quality of life can be restored.”

According to the Centers for Disease Control and Prevention (CDC), approximately 5.7 million adults in the US have heart failure. Within five years of diagnosis, around 50 percent of patients with heart failure will die of the condition.


Keywords: Medical Device, Heart Failure, Anticoagulants


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.